SCHEMBL4033230

SCHEMBL4033230

CCCn1nc(-c2ccc(OC)cc2)c2c(C)ccc(F)c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.42
LMNA P02545 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
TSHR P16473 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TGM2 P21980 1/20 0.36
TGM1 P22735 1/20 0.36
CASP3 P42574 1/20 0.36
TGM3 Q08188 1/20 0.36
TP53 P04637 2/20 0.36
PRKDC P78527 1/20 0.36
MAPT P10636 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LTA4H P09960 1/20 0.35
CACNA2D1 P54289 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636903 0.81 ESR1 (0.39) ESR1LMNAKDM4EALDH1A1GAA
SCHEMBL4031181 0.79 ESR1 (0.54) ESR1LMNAKDM4EALDH1A1MEN1
SCHEMBL4030745 0.78 ALDH1A1 (0.40) LMNAKDM4EALDH1A1GAATSHR
SCHEMBL5411726 0.78 SRC (0.50) TP53PRKDC
SCHEMBL4034796 0.75 ESR1 (0.73) ESR1LMNAKDM4EALDH1A1GAA
SCHEMBL5634746 0.73 SMPD1 (0.41) ESR1MEN1KMT2ANPC1RAB9A
SCHEMBL4035160 0.71 ESR1 (0.50) ESR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL4027614 0.70 ESR1 (0.55) ESR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL4030093 0.70 CRHR1 (0.44) ESR1
SCHEMBL4027997 0.69 ESR1 (0.73) ESR1KDM4EALDH1A1NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2004-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR ESR1 1028/4885LMNA 4029/4885KDM4E 339/4885
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols INSR, MSR1, TNNI3 ESR1 2487/4885LMNA 4285/4885KDM4E 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.